1. Cardioprotection of Canagliflozin, Dapagliflozin, and Empagliflozin: Lessons from preclinical studies
   Rayla Rodrigues Soares et al, 2024, Chemico-Biological Interactions CrossRef
2. Schisandrin B Diet Inhibits Oxidative Stress to Reduce Ferroptosis and Lipid Peroxidation to Prevent Pirarubicin-Induced Hepatotoxicity
   Hongwei Shi et al, 2022, BioMed Research International CrossRef
3. Bibliometric and visual analysis of SGLT2 inhibitors in cardiovascular diseases
   Runfang Pan et al, 2024, Frontiers in Pharmacology CrossRef
4. SGLT2-i prevent left ventricular dysfunction induced by anthracycline in mouse model: A systematic-review and meta-analysis
   Andrea Faggiano et al, 2023, Vascular Pharmacology CrossRef
5. Wogonin reduces cardiomyocyte apoptosis from mitochondrial release of cytochrome c to improve doxorubicin‑induced cardiotoxicity
   Yunjie Wei et al, 2022, Experimental and Therapeutic Medicine CrossRef
6. Cardioprotection of cancer patients receiving cardiotoxic chemotherapy — current status
   Anton K. Peresada et al, 2024, Journal of Clinical Practice CrossRef
7. Reducing oxidative stress may be important for treating pirarubicin‑induced cardiotoxicity with schisandrin B
   Heng Tang et al, 2021, Experimental and Therapeutic Medicine CrossRef
8. Canagliflozin mitigates ferroptosis and improves myocardial oxidative stress in mice with diabetic cardiomyopathy
   Shuqin Du et al, 2022, Frontiers in Endocrinology CrossRef